secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001193125-22-146350
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q1 net loss $79.1M ($0.36/share); CEO Kim resigns, Shea appointed; discontinues INNOVATE trial
--------------------------------------------------------------------------------

- Net loss $79.1M ($0.36/share) vs $54.4M ($0.27) in Q1 2021; revenue $199K.
- CEO J. Joseph Kim resigns; Jacqueline Shea (former COO) appointed President and CEO; Shea base salary $700K.
- Phase 3 INNOVATE trial for COVID-19 vaccine discontinues; prioritize heterologous booster strategy.
- VGX-3100 BLA for cervical HSIL not expected in 2023; REVEAL2 amended to biomarker-selected population.
- Cash and investments $360.4M at Mar 31, 2022, down from $401.3M at Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/0001193125-22-146350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/d259881d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-146350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer